Kornimate/medical-research-clean huggingface dataset:
magnetic resonance imaging-guided adaptive radiotherapy for large brain metastases

Conditions: Brain Metastases

Summary: this study is an ambispective cohort study to evaluate the displacement and deformation of large brain metastases (bm) treated with magnetic resonance imaging-guided adaptive radiotherapy (mrigart)

all patients had a pathologically confirmed malignant cancer and were diagnosed with brain metastases (bm) by enhanced magnetic resonance imaging (mri) with bm volume of 2cm and above. all patients received unity mr-linac adaptive radiotherapy. gross tumor volume (gtv) and organs at risk (oars) were re-delineated for every image set and analyzed for displacement and deformation.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years; kps score ≥ 60. 2. pathologically confirmed lung cancer. 3. diagnosed with brain metastases by enhanced mri. 4. bm volume ≥ 2cm. 5. anticipated time to survival\>3 months. 6. treated with unity mr-linac. 7. good compliance; able to stay still in supine position for 45 minutes and above. exclusion criteria: 1. fail to complete radiotherapy as planned; anticipated time to survival less than 3 months. 2. suffer from severe back pain in supine position, unable to receive unity mr-linac. 3. suffer from severe claustrophobia. 4. incomplete pre-unity image data.

Keywords: magnetic resonance imaging-guided adaptive radiotherapy
evaluation of efficacy and safety of naftin 1% cream in adolescent subjects with tinea cruris

Conditions: Tinea Cruris; Jock Itch

Summary: to see how well naftin 1% cream works when applied once daily to the affected area. the results will be compared to those using a placebo cream, which is a cream with no active ingredient. safety will also be measured.


Eligibility criteria:
inclusion criteria: * review and sign statement of informed consent and hipaa authorization. * males or non-pregnant females ≥ 12 years of age to 17 years, 11 months, of any race or sex. females of child-bearing potential must have a negative urine pregnancy test. * the parent/legal guardian must complete the informed consent process and the subject must complete the assent process and sign the appropriate form (if age appropriate). * presence of tinea cruris characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus) based on signs and symptoms. * koh positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity. * subjects must be in good health and free from any clinically significant disease that might interfere with the study evaluations. * subject must be able to understand the requirements of the study and willing to comply with the study requirements. exclusion criteria: * a life threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months. * subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.- severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection. * subjects with a known hypersensitivity to study medications or their components. * subjects who have a recent history or who are currently known to abuse alcohol or drugs. * uncontrolled diabetes mellitus. * hemodialysis or chronic ambulatory peritoneal dialysis therapy. * current diagnosis of immunocompromising conditions. * atopic or contact dermatitis. * severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection. * female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study (females who are surgically sterilized for at least 2 years are not considered to be of childbearing potential). * subjects using the following medications: * topical anti-fungal therapy, powders or topical corticosteroids applied within 14 days prior to randomization. terbinafine, butenafine, and naftifine (topical) within 30 days prior to randomization. * oral anti-fungal therapies within 3 months of randomization (8 months for oral terbinafine). * systemic antibiotic or corticosteroid treatment within 30 days of randomization. * any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.
parkinson's disease g2019s lrrk2 genetic testing program

Conditions: Parkinson's Disease

Summary: increase awareness of the g2019s lrrk2 mutation in parkinson's and no cost genetic testing program.

this program is intended to increase awareness of genetic parkinson's, in particular the g2019s lrrk2 mutation, and provide no cost genetic testing to determine if they carry the g2019s lrrk2 mutation.

Eligibility criteria:
participants include those with a clinical diagnosis of parkinson's, in particular those who have a first- or second-degree relative with parkinson's, or who have young onset parkinson's (age less than 50 at diagnosis) or are of ashkenazi jewish or north african berber descent, or have a relative with a known genetic mutation in the lrrk2 gene, or who have a genetic mutation in the lrrk2 gene. inclusion criteria: participant eligible for enrollment in the program must meet all of the following criteria: 1. participant must be a person diagnosed with parkinson's disease who is 18 years or older. 2. participant is under the care of a physician for their parkinson's disease. 3. participant is able to read, write and understand english, and reside in a country where the shipment of biological samples is allowed. 4. participant is able to grant informed consent. 5. in the case of participants, willing to participate in a free genetic testing program to determine if they carry the g2019s lrrk2 mutation. 6. willing to be notified of eligibility for clinical studies (if appropriate). 7. particpants who already believe they have tested positive for the mutation will be allowed to be retested through this program and be notified of potential eligibility for studies. exclusion criteria: 1. inability to meet any of the inclusion criteria. 2. participant has received on of the following advanced treatments to manage their parkinson's: gene therapy, deep brain stimulation (dbs), injections into the brain, continuous infusion of medication into their stomach/intestines with a pump.

Keywords: g2019s lrrk2 mutation young onset genetic ashkenazi jewish descent north african berber
estrogen variability and irritability during the menopause transition

Conditions: Menopause; Irritable Mood

Summary: women in the menopause transition (perimenopause) experience substantial day-to-day variability in estradiol and have a 2-4-fold increase in major depression risk. about 40% of perimenopausal women are susceptible to the emergence of affective symptoms tied to changes in estradiol. among the perimenopausal women with affective impairment, most report irritability, not "depression," is their primary source of impairment and distress. the purpose of this research is to determine the neurophysiologic basis of susceptibility to estradiol fluctuations and irritability symptoms in perimenopausal women.

using a within-subjects, cross-over design and transdermal estradiol to stabilize estradiol fluctuations (and increase levels) the investigators will test if neural dynamics (oscillatory activity in the theta and beta frequencies assessed via eeg) associated with key constructs of irritability (attentional bias to threat and frustration to non-reward) represent a biomarker target of irritability symptom response to transdermal estradiol.

Eligibility criteria:
inclusion criteria: * healthy women 45 - 59 years of age * in the early menopause transition (defined by variable menstrual cycle length that is 7+ days longer or shorter than usual) * increase in irritability since the onset of menstrual cycle changes * moderate to severe irritability symptoms, as defined by idas ill-temper scale score \>10 * have experienced 1+ very stressful life event (e.g. divorce, death of family member) within the past 6 months * negative mammogram within the past two years * bmi between 18 - 45 kg/m\^2 exclusion criteria: * use of psychotropic agents or hormonal preparations, or herbal supplements (other than multivitamins) believed to affect mood or menopausal symptoms * history of psychosis, bipolar disorder, or substance dependence * active psychological symptoms severe enough to require treatment * current suicidal intent or recent history of suicide attempts (within past 10 years) * personal or family history of cancer indicative of more than average risk for breast, ovarian or endometrial cancers * personal history of any cardiovascular disease including coronary artery disease, arteriosclerosis, heart attack, stroke * personal history of thromboembolic disorders * history of e2-dependent neoplasia * history of gallbladder disease * recent history of migraine with aura * blood pressure classified as higher than stage 2 hypertension (≥160 mmhg systolic or ≥100 mmhg diastolic) * liver dysfunction or disease * undiagnosed abnormal genital bleeding * type i diabetes * known sensitivities to the matrix patch system in climara® or allergy to peanut oil used in prometrium®

Keywords: perimenopause menopause transition estrogen stress mood irritability
intraoral maxillary protraction technique vs facemask using alt-ramec protocol for treatment class iii growing patients

Conditions: Orthodontic Appliance Complication

Summary: the study compares use of intraoral technique for maxillary advancement and extra oral technique with hep of protocol called alt-ramec which depends on repeated expansion and constriction of maxilla to help in maxillary protraction

delivering hybrid expander supported by 2 miniscrews in palate to perform alt-ramec protocol for 9 weeks then intervention group will start protraction using class iii elastics on modified lingual arch with hooks in canine area and 2 miniscrews labially between lower lateral and canine while control group use face mask for protraction of maxilla

Eligibility criteria:
inclusion criteria: * male or female growing patient ( cvm2-cvm3 ) * skeletal class iii (anb ≤ 0 , a-nv≤ -2 and wits appraisal \< -0.3mm) * erupted upper and lower first permanent molars and permanent incisors * reverse overjet up to -4 mm exclusion criteria: * history of previous orthodontic treatment * cleft lip/palate patients * patients with habits that are detrimental to dental occlusion (thumb sucking, tongue thrusting). * patients with syndromes
invasive pulmonary aspergillosis and severe influenza

Conditions: Aspergillosis; Influenza; Critical Illness

Summary: invasive pulmonary aspergillosis (ipa) has been reported in critically ill patients with influenza infection with a highly variable incidence between 1 to 21%. studies investigating ipa in critically ill patients with influenza infection suffer limitations in their methods. it remains unknown whether patients with influenza are more at risk of ipa than other patients hospitalized in intensive care unit and whether patients with influenza who develop ipa have specific risk factors for this infection. our study aims to determine the incidence of ipa in a large multicenter cohort and to identify risk factors for ipa in these patients.


Eligibility criteria:
inclusion criteria: * infection with influenza a or b * admission to one of the participating sites exclusion criteria: * age \< 18 * patients with invasive pulmonary aspergillosis prior to intensive care admission * consent withdraw
a study of ketorolac for the treatment of inflammation and pain associated with cataract surgery

Conditions: Cataract Extraction

Summary: this is a 16 day study to evaluate the safety and efficacy of ketorolac eye drops for the treatment of inflammation and pain associated with cataract surgery


Eligibility criteria:
inclusion criteria: * patients undergoing cataract surgery exclusion criteria: * uncontrolled ocular disease in cataract surgery eye
hyaluronic acid and adelmidrol (hyadrol®) in patients with degenerative joint disease

Conditions: Degenerative Joint Disease

Summary: osteoarthritis is a major cause of chronic musculoskeletal pain. behind this disorder there is a process of chronic neuroinflammation due to the overactivation of mast cells at the tissue level. the mast cells present in the synovial membranes act as first sensors in pathological situations, degranulating in an uncontrolled manner. furthermore, in degenerative joint pathologies, there is a marked reduction in the viscoelastic capacity of the synovial fluid associated with a reduction in both the concentration and the average molecular weight of endogenous hyaluronic acid. the association of hyaluronic acid and adelmidrol (hyadrol®) could represent an effective treatment for controlling the neuroinflammation process that supports degenerative joint diseases. the objective of the present clinical investigation is to evaluate its safety and efficacy in patients with arthritis of the hip (coxarthrosis) and trapezium-metacarpal joints (rhizoarthrosis).


Eligibility criteria:
inclusion criteria: * age ≥ 40 years; * both genders; * diagnosis of stage ii-iii coxarthrosis or rhizoarthrosis according to radiological classification (kellgren and lawrence or modified eaton-littler criteria respectively) * pain intensity ≥ 5 on nrs; * wash-out for at least two weeks from anti-inflammatory drugs before enrollment; * compliant patients; * signed informed consent. exclusion criteria: * age \< 40 years; * presence of concomitant inflammatory systemic pathologies (e.g.: rheumatoid arthritis, etc.); * severe and progressive clinical conditions, * nsaids therapy in the 2 weeks prior to enrollment; * corticosteroid therapy in the 3 months prior to enrollment; * chondroprotectors intake in the 6 months prior to enrollment; * arthroscopic procedures or intra-articular visco-supplementation in the 6 months prior to enrollment; * presence of cognitive impairment; * ongoing rehabilitation and/or physiotherapy; * allergy or hypersensitivity to the study treatment; * pregnant and/or lactating female subjects; * not compliant patients; * denied informed consent.
phase i safety and immunogenicity of live attenuated influenza h5 candidate vaccine strain a/17/turkey/turkey/05/133 (h5n2) in healthy thai volunteers

Conditions: Preventive Avian Flu

Summary: the purpose of this study is to evaluate safety and reactogenicity of live attenuated influenza h5 vaccine candidate strain a/17/turkey/turkey/05/133 (h5n2) manufactured by gpo, in thailand to previously healthy thais.

it is a phase i randomized placebo controlled trial (vaccine and placebo ratio of 2:1). a phase ii study is planned to be conducted following review of results of this phase. phase i: it is a double blind randomized placebo controlled trial involving 24 participants age 18-49 years (16 will receive vaccines and 8 will receive placebo). all will be admitted in the isolation ward for 10-14 days after each immunization mainly for safety assessment. two doses of live attenuated influenza h5 vaccine candidate strain a/17/turkey/turkey/05/133 (h5n2) will be given by intranasal route 21 days apart. each group of 4 participants will be immunized at a time at 30-60 mins interval. all participants will be followed 21 days after each immunization. total follow up is 60 day.

Eligibility criteria:
inclusion criteria: * healthy * age 18-49 years old * having thai id card or equivalent * are seronegative to the specific h5 influenza virus determined by antibody titer less than 1:40 by hai test to the corresponding antigen. * anti hiv - negative * all hematology \& biochemistry and urine analysis are within normal range or of no clinical significance (not more than 1.5 times of normal value) * able to read and write and sign written informed consent. exclusion criteria: * known history of egg allergy * having had recently influenza infection confirmed as h5 * history of bronchial asthma * history of chronic lung diseases * history of chronic rhinitis * history of immunodeficiency state * history of immunosuppression * history of heavy smoking (more than 5 rolls per day) * history of alcoholic (pure drink 200 ml per day) * acute infectious and noninfectious diseases (within 2 weeks) * exacerbation of chronic diseases or cancer or hiv positives * anamnestic leukocytosis, hepatitis b and c positives * the volunteers who have been taking immunoglobulin products or have had a blood transfusion during past three months before the beginning of the experiment * participation in other research study or stop participant less than 1 month * pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding * any concomitant medication with aspirin * the volunteers who have family members with immunodeficiency * poultry workers * have undertaken international travel within the one week prior to immunization

Keywords: avian flu h5n2
proteomics in small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: the aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.

the study will include 50 patients with newly diagnosed sclc, referred to systemic antineoplastic treatment at the dept. of oncology, aalborg university hospital and blood samples from 50 healthy blood donors. the blood samples from sclc patients will be collected before chemotherapy with carboplatin and etoposide and after 2 cycles of chemotherapy. imaging will be performed at the dept. of radiology, aalborg university hospital before chemotherapy and after 3 cycles of the treatment.

Eligibility criteria:
inclusion criteria: * written and signed informed consent * histopathologically and/or cytologically newly-diagnosed sclc * measurable disease on ct scans * eligibility to receive standard chemotherapy consisting of carboplatin and etoposide exclusion criteria: * active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ * prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ * concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed) * treatment with any other investigational agent

Keywords: proteomics biomarkers
personalized blood pressure care using iomts and artificial intelligence

Conditions: Pre-hypertension

Summary: in this rct, up to 100 adults classified as pre-hypertensive will be randomized to either an artificial intelligence (ai) based lifestyle intervention group or an active control group with a 1 to 1 ratio. both groups will receive an identical activity tracker (samsung galaxy watch) and bp monitor (omron evolv). the ai intervention group will receive automated and personalized lifestyle recommendations based on their lifestyle (e.g. sleep, exercise and diet) and blood pressure (bp) data, involving an automated analytics engine using statistics and machine learning. the active control group will not receive these lifestyle recommendations. the investigators aim to assess objectively the effectiveness of the ai-based personalized lifestyle recommendations on the patients bp.


Eligibility criteria:
inclusion criteria: * age ≥18 years * sbp between 130 mmhg to 139 mmhg or/and dbp between 80 to 89 mmhg in a research office * speaking and reading english * having an iphone 8 or newer or an android x or newer exclusion criteria: * currently taking antihypertensive medication * self-reported diagnosis of coronary heart disease, medical condition or other physical problem necessitating special attention in an exercise program (e.g., cancer, eating disorder, uncontrolled diabetes) * current participation in a lifestyle modification program or research study * self-report of being currently pregnant
cost-effectiveness of lung volume reduction surgery

Conditions: Chronic Obstructive Pulmonary Disease; Emphysema

Summary: lung volume reduction surgery (lvrs) has been advanced as a therapy to significantly improve quality of life in patients with copd, but to date no controlled studies have evaluated the impact of lvrs.

background: lung volume reduction surgery (lvrs) has been advanced as a therapy to significantly improve quality of life in patients with copd, but to date no controlled studies have evaluated the impact of lvrs. objectives: evaluate cost-effectiveness of lvrs compared to current therapy for copd. methods: this is a case control study in which veterans undergoing lvrs at va puget sound health care system (vapshcs) are compared to patients with a similar severity of disease at boise vamc who are not undergoing lvrs. changes in health related quality of life are being evaluated using three instruments: the sf-36, the st. george�s respiratory questionnaire, and the quality of well-being scale, the latter to calculate utility associated with different health states. costs will be determined using utilization data on outpatient visits, medications, oxygen use, inpatient days, radiology tests, laboratory tests, and emergency room visits are being collected for the twelve months before and after surgery. costs will be calculated according to va and community standards. status: complete.

Eligibility criteria:
inclusion criteria: severe copd as defined by fev1 of 20-30% predicted; marked hyperinflation with a residual volume of \>165% predicted; 6-min walk greater than 600 ft; abstinence from cigarette smoking for 3-mths; absence of co-morbid illnesses that would significantly increase surgical risk, such as severe coronary artery disease exclusion criteria:
ready to use therapeutic food (rutf) to promote growth in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: children with cystic fibrosis require increased caloric intake to maintain appropriate growth, an important determinant of long-term outcomes. this study seeks to determine the feasibility of using a novel therapeutic food to promote weight gain and growth in children with cystic fibrosis.


Eligibility criteria:
inclusion criteria: * cystic fibrosis diagnosed by sweat test or genetic testing. * exocrine pancreatic insufficiency and receiving pancreatic enzyme replacement therapy * bmi or weight for age of less than the 50th percentile exclusion criteria: * cystic fibrosis related diabetes mellitus * cystic fibrosis related liver disease. * anaphylactic or other allergy to peanut, cow's milk, oat flour or other rutf ingredients. * patients who are status-post lung or liver transplantation * currently receiving enteral supplemental nutrition through gastrostomy or nasogastric tube.